Quarterly ResultMay 11, 2026, 04:18 PM
Sana Biotechnology Reports Q1 Net Loss of $47.2M; Going Concern Doubt
AI Summary
Sana Biotechnology reported a net loss of $47.2 million for the first quarter of 2026, an improvement from $49.4 million in the prior year. Despite the reduced loss, management expressed substantial doubt about the company's ability to continue as a going concern for at least one year due to insufficient capital resources. The company has an amended at-the-market facility to sell up to $150.0 million in common stock, though no shares were sold during the quarter.
Key Highlights
- Management identified substantial doubt about Sana Biotechnology's ability to continue as a going concern for at least one year.
- Net loss for Q1 2026 was $47.21 million, down from $49.39 million in Q1 2025.
- Net loss per common share was $(0.17) for Q1 2026, compared to $(0.21) in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $101.1 million as of March 31, 2026.
- Total operating expenses decreased to $48.61 million in Q1 2026 from $50.63 million in Q1 2025.
- Research and development expenses were $28.72 million in Q1 2026, a decrease from $37.19 million in Q1 2025.
- An amended ATM facility allows for the sale of up to $150.0 million in common stock, with no sales in Q1 2026.
- Contingent consideration liability was $134.5 million as of March 31, 2026, with a $10.7 million expense recognized.